The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer
Open accessAbstract
Epithelial-mesenchymal transition (EMT) is an initiating event in tumor cell invasion and metastasis. It has been shown to occur in resistance to a range of cancer therapies, including tamoxifen. MicroRNAs (miRNAs) have been associated with EMT as well as resistance to standard therapies. To investigate the role of miRNAs in the development of resistance to tamoxifen as well as accompanying EMT-like properties, we established a tamoxifen-resistant (TamR) model by continually exposing MCF-7 breast cancer cells to tamoxifen. In addition to the molecular changes known to be involved in acquired tamoxifen resistance, TamR cells displayed mesenchymal features and had increased invasiveness. Genome-wide miRNA microarray analysis revealed that miRNA-375 was among the top downregulated miRNAs in resistant cells. Re-expression of miR-375 was sufficient to sensitize TamR cells to tamoxifen and partly reversed EMT. A combination of mRNA profiling, bioinformatics analysis and experimental validation identified metadherin (MTDH) as a direct target of miR-375. Knockdown of MTDH partially phenocopied the effects of miR-375 on the sensitivity to tamoxifen and the reversal of EMT. We observed an inverse correlation between the expression of miR-375 and its target MTDH in primary breast cancer samples, implying the pathological relevance of targeting. Finally, tamoxifen-treated patients with higher expression of MTDH had a shorter disease-free survival and higher risk of relapse. As most cancer-related deaths occur because of resistance to standard therapies and metastasis, re-expression of miR-375 or targeting MTDH might serve as potential therapeutic approaches for the treatment of TamR breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Role of cell shape in growth control
Folkman, J., & Moscona, A. (1978) · Nature · doi:10.1038/273345a0 · Cited by 2,422
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
Dweep, H., Sticht, C., Pandey, P., & Gretz, N. (2011) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2011.05.002 · Cited by 1,696
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Ma, X.-J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.015 · Cited by 954
Pawitan, Y., Bjöhle, J., Amler, L., Borg, A.-L., Egyhazi, S., Hall, P., Han, X., Holmberg, L., Huang, F., Klaar, S., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1325 · Cited by 831
Self-citationEger, A., Aigner, K., Sonderegger, S., Dampier, B., Oehler, S., Schreiber, M., Berx, G., Cano, A., Beug, H., & Foisner, R. (2005) · Oncogene · doi:10.1038/sj.onc.1208429 · Cited by 808
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., Jacob, S., & Majumder, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804612200 · Cited by 749
Ladeiro, Y., Couchy, G., Balabaud, C., Bioulac-Sage, P., Pelletier, L., Rebouissou, S., & Zucman-Rossi, J. (2008) · Hepatology · doi:10.1002/hep.22256 · Cited by 684
Modelling breast cancer: one size does not fit all
Vargo-Gogola, T., & Rosen, J. M. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2193 · Cited by 679
Li, Y., VandenBoom, T. G., Kong, D., Wang, Z., Ali, S., Philip, P. A., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1298 · Cited by 663
Mechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
Hu, G., Chong, R. A., Yang, Q., Wei, Y., Blanco, M. A., Li, F., Reiss, M., Au, J. L.-S., Haffty, B. G., & Kang, Y. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.11.013 · Cited by 420
Endocrine Pharmacology of Antiestrogens as Antitumor Agents*
JORDAN, V. C., & MURPHY, C. S. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-4-578 · Cited by 400
Tsukamoto, Y., Nakada, C., Noguchi, T., Tanigawa, M., Nguyen, L. T., Uchida, T., Hijiya, N., Matsuura, K., Fujioka, T., Seto, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2777 · Cited by 392
Sahin, Ö., Fröhlich, H., Löbke, C., Korf, U., Burmester, S., Majety, M., Mattern, J., Schupp, I., Chaouiya, C., Thieffry, D., et al. (2009) · BMC Systems Biology · doi:10.1186/1752-0509-3-1 · Cited by 335
Self-citationEpithelial mesenchymal transition traits in human breast cancer cell lines
Blick, T., Widodo, E., Hugo, H., Waltham, M., Lenburg, M. E., Neve, R. M., & Thompson, E. W. (2008) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9170-6 · Cited by 314
miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors
Enerly, E., Steinfeld, I., Kleivi, K., Leivonen, S.-K., Aure, M. R., Russnes, H. G., Rønneberg, J. A., Johnsen, H., Navon, R., Rødland, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016915 · Cited by 310
Buffa, F. M., Camps, C., Winchester, L., Snell, C. E., Gee, H. E., Sheldon, H., Taylor, M., Harris, A. L., & Ragoussis, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0489 · Cited by 308
Hiscox, S., Morgan, L., Green, T. P., Barrow, D., Gee, J., & Nicholson, R. I. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9120-9 · Cited by 274
de Souza Rocha Simonini, P., Breiling, A., Gupta, N., Malekpour, M., Youns, M., Omranipour, R., Malekpour, F., Volinia, S., Croce, C. M., Najmabadi, H., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1318 · Cited by 267
Self-citationHiscox, S., Jiang, W. G., Obermeier, K., Taylor, K., Morgan, L., Burmi, R., Barrow, D., & Nicholson, R. I. (2006) · International Journal of Cancer · doi:10.1002/ijc.21355 · Cited by 260
Sun, L., Yao, Y., Liu, B., Lin, Z., Lin, L., Yang, M., Zhang, W., Chen, W., Pan, C., Liu, Q., et al. (2012) · Oncogene · doi:10.1038/onc.2011.263 · Cited by 249
Kong, K. L., Kwong, D. L. W., Chan, T. H.-M., Law, S. Y.-K., Chen, L., Li, Y., Qin, Y.-R., & Guan, X.-Y. (2012) · Gut · doi:10.1136/gutjnl-2011-300178 · Cited by 238
Cariou, S., Donovan, J. C. H., Flanagan, W. M., Milic, A., Bhattacharya, N., & Slingerland, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160016897 · Cited by 224
Uhlmann, S., Zhang, J. D., Schwäger, A., Mannsperger, H., Riazalhosseini, Y., Burmester, S., Ward, A., Korf, U., Wiemann, S., & Sahin, Ö. (2010) · Oncogene · doi:10.1038/onc.2010.201 · Cited by 199
Self-citationBergamaschi, A., & Katzenellenbogen, B. S. (2012) · Oncogene · doi:10.1038/onc.2011.223 · Cited by 181
Katzenellenbogen, B. S., MILLER, M. A., Mullick, A., & Sheen, Y. Y. (1985) · Breast Cancer Research and Treatment · doi:10.1007/bf01806018 · Cited by 109
Kim, M. R., Choi, H., Cho, K. B., Kim, H. S., & Kang, K. W. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01260.x · Cited by 101
Epigenetic regulation of microRNA‐375 and its role in melanoma development in humans
Mazar, J., DeBlasio, D., Govindarajan, S. S., Zhang, S., & Perera, R. J. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.06.025 · Cited by 89
Li, X., Kong, X., Huo, Q., Guo, H., Yan, S., Yuan, C., Moran, M. S., Shao, C., & Yang, Q. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01919.x · Cited by 78
Long-Term Exposure to Tamoxifen Induces Hypersensitivity to Estradiol
Berstein, L. M., Wang, J., Zheng, H., Yue, W., Conaway, M. R., & Santen, R. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0433-03 · Cited by 57
Cited by
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Sang, Y., Chen, B., Song, X., Li, Y., Liang, Y., Han, D., Zhang, N., Zhang, H., Liu, Y., Chen, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.011 · Cited by 460
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells
Wei, Y., Lai, X., Yu, S., Chen, S., Ma, Y., Zhang, Y., Li, H., Zhu, X., Yao, L., & Zhang, J. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3037-0 · Cited by 354
Self-citationvan Schooneveld, E., Wildiers, H., Vergote, I., Vermeulen, P. B., Dirix, L. Y., & Van Laere, S. J. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0526-y · Cited by 296
Metadata
- Authors
- Ward, A., Balwierz, A., Zhang, J. D., Küblbeck, M., Pawitan, Y., Hielscher, T., Wiemann, S., & Sahin, Ö.
- Venue
- Oncogene
- Published
- 2012-04-16
- Volume
- 32
- Issue
- 9
- Pages
- 1173-1182
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2004102172
- Cited by
- 280
- References
- 36
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.